The Committee for Medicinal Products for Human Use (CHMP) decided that Intrinsa’ s benefits are greater than its risks for the treatment of hypoactive sexual desire disorder in bilaterally oophorectomised and hysterectomised women receiving concomitant oestrogen therapy.